agenT-797,pembrolizumab,nivolumab
mink therapeutics,bms,merck
[]
mink-413 is a next-generation armored allo-bcma-car-inkt. our #sitc2022 preclinical data demonstrate its effective bone marrow homing, and potent cytotoxic activity, with soluble il-15 prolonging persistence. 